31
Participants
Start Date
July 8, 2020
Primary Completion Date
April 25, 2025
Study Completion Date
April 25, 2025
TP-1454 monotherapy
Flat dose once or twice daily, alone
University of Virginia, Charlottesville
Mayo Clinic Jacksonville, Jacksonville
Vanderbilt University, Nashville
Medical College of Wisconsin, Milwaukee
Mayo Clinic Rochester, Rochester
Texas Oncology Baylor Sammons Cancer Center, Dallas
MD Anderson Cancer Center, Houston
Huntsman Cancer Institute, Salt Lake City
Mayo Clinic Arizona, Phoenix
Comprehensive Cancer Center of Nevada, Las Vegas
University of Southern California - Norris Cancer Center and Hoag Memorial Hospital, Los Angeles
Sumitomo Pharma America, Inc.
INDUSTRY